Atopic Dermatitis

Strategies that can be used by healthcare professionals to help address patient concerns around atopic dermatitis.

Advice for healthcare professionals who treat atopic dermatitis to help them best manage patients and connect them to other supportive resources.

A new study sheds light on some of the atopic disease risks that are associated with early childhood and continue into midlife.

The importance of partnering with patients who have atopic dermatitis to best support them throughout their long-term journey with the condition.

Considerations regarding how to best select from and use newer therapies for atopic dermatitis.

Investigators push for a greater understanding of the disease in relation to the mental health of young patients, which has affected roughly 20% of the global pediatric population.

Recent phase 3 trial data confirms that dupilumab is the first biologic medicine is the first to reduce severity and symptoms of atopic dermatitis in pediatric patients.

Current barriers faced by healthcare professionals who treat atopic dermatitis and anticipation regarding opportunities emerging in the field.

Strategies used to evaluate patients and accurately diagnose atopic dermatitis in children and adults.

Experts in dermatology discuss patient education and clinical pearls to assist colleagues in the management of atopic dermatitis.

The authors of a recent review recommend continued research on “powerful” new treatment methods that are effective in treating atopic diseases such as atopic eczema.

Investigators believe their study shows the efficacy and safety of the 2 biologic agents, which are known to have anti-inflammatory and immunosuppressant qualities.

Margaret Bobonich, DNP, FNP-C, DCNP, FAANP, and Douglas DiRuggiero, DMSc, PA-C, provide insight into the emerging class of JAK inhibitors for atopic dermatitis including their pathophysiology, route of administration, and available clinical evidence.

Patient factors and disease characteristics that impact one’s treatment approach for atopic dermatitis.

Key players in dermatology clinics and steps taken to help patients receive access to newer therapies available to treat atopic dermatitis.

Margaret Bobonich, DNP, FNP-C, DCNP, FAANP, and Douglas Di Ruggiero, DMSc, PA-C, provide an overview of current and emerging systemic therapies for atopic dermatitis.

The good care practices cited in the study can lead to increased care of patients with atopic dermatitis and are able to be implemented in any practice.

Recent data from phase 3 clinical trials of the antibody shows significant skin clearance and itch in people with atopic dermatitis.

Reactions to the efficacy and safety of dupilumab treatment for atopic dermatitis as demonstrated by clinical trial data and real-world experience.

Experts in dermatology describe the topical treatment landscape of atopic dermatitis: corticosteroids, calcineurin inhibitors, crisaborole, and upcoming topical JAK inhibitors.

Keri Holyoak, PA-C, MPH, reacts to the FDA approval of dupilumab for atopic dermatitis and explains what makes this therapy unique compared to other treatment options.

Margaret Bobonich, DNP, FNP-C, DCNP, FAANP, and Douglas DiRuggiero, DMSc, PA-C discuss best practices in the non-pharmacologic management of atopic dermatitis including elimination of triggers, bathing, and reducing infection risk.

According to a claims analysis, sunburn was also commonly diagnosed in female and young patients.

Investigators link early atopic manifestations and other complications to tree nut allergy, which account for most of all food related deaths by anaphylaxis.

The prevalence of striae distensae was notably higher in psoriasis than atopic dermatitis.